



JMCC Group Boosts European Presence with Acquisition of EU GMP-Certified Cannabis Production Facility in Malta

May 15, 2023

JMCC Group is pleased to announce that we have acquired Materia Malta's world-class, EU GMP-certified manufacturing facility as well as all other assets of the company's Maltese medical cannabis operations.

Materia Malta's 32,000-square-foot processing facility is ideally suited to dovetail with JMCC's other pharma-level infrastructure, including our company's 135,000-square-foot GACP cultivation site and 20,000-square-foot processing centre in Jamaica. It will also complement our GDP-certified warehousing and distribution facility, JMCC European Distribution Ltd, located between England and France on the Channel Island of Jersey.

The acquisition significantly accelerates JMCC's operations in Europe and the United Kingdom and positions us to better support patients throughout the region. It also reinforces our company's ability to align with market demand for JMCC's naturally grown, medical-grade dried cannabis flower and our unique nano-emulsified formulations.

The entity will be renamed JMCC Life Sciences, Europe.

Benefits for Partners and Customers

JMCC will continue to work with highly experienced and respected medical distributors, clinics and other strategic partners to get our products to prescribers and patients in other regions, including Oceania and Asia.

Diane Scott, JMCC Group Chair & CEO noted that the addition of the Malta operation is aligned with the company's strategic commitment to focus 100% on the medical market. In 2018, Malta enacted the *Production of Cannabis for Medicinal and Research Purposes Act* to provide the legal framework for production, following the amendment of its *Drug Dependence Act* to allow prescriptions for medicinal preparations of cannabis. The country introduced a legal regime for adult use of cannabis in 2022. But, as in other countries where adult/recreational use has been legalized, JMCC will stick to the medical side only.

"From the start, we made a commitment to both patients and healthcare professionals globally that JMCC will invest in the R&D and enterprise-wide quality assurance required to produce science-led and pharma-like products that are safe and effective as well as easier for patients and prescribers to use," Diane said. "And we're sticking with that promise, despite the financial appeal the rec market might appear to offer. The medical side is just a lot more interesting for us and it's where the talents of our terrific global team are focused."



The new facility in Malta and our Jersey warehousing and distribution hub will also enable JMCC Group to offer producers and manufacturers of high-value medical products in North America, Europe, the UK and other countries an unbeatable suite of EU GMP-certified processing, packaging and GDP-certified logistics services to facilitate their international sales.

For more information, please contact info@jmccgroup.com and we'll direct your enquiry to the right JMCC team member.